Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Ad26.COV2.S COVID-19 prevention study in adults
2020-003643-29Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2020
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ad26.COV2.S with Placebo (2 arms). Primary endpoint: First occurrence of molecularly confirmed moderate to severe/critical COVID-19. Status: unknown.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003643-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003643-29.